Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer

Bristol Myers Squibb (BMS) has appointed Chris Shibutani, M.D., a former senior biotech equity analyst at Goldman Sachs, as its new executive vice president and chief strategy officer, effective June 2025123.

Shibutani will oversee BMS's long-term strategy, including approaches to external partnerships and institutional collaborations1.

He brings 25 years of industry experience, including roles as managing director for biotech equity research at both Goldman Sachs and TD Cowen, and a medical background as a former anesthesiologist and clinical instructor12.

Shibutani holds a medical degree from Columbia University and an MBA from Columbia Business School1.

His appointment continues a trend of major pharmaceutical companies hiring Wall Street analysts with medical or scientific backgrounds to lead strategic efforts1.

Sources:

1. https://www.fiercebiotech.com/biotech/bms-taps-wall-street-analyst-goldman-sachs-lead-long-term-strategy

2. https://firstwordpharma.com/story/5972860

3. https://www.roi-nj.com/2025/06/13/healthcare/bristol-myers-squibb-names-shibutani-as-evp-chief-strategy-officer/